Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis

被引：0

作者：

Bunick, Christopher G. ^{[1
,2
]}

Bhatia, Neal ^{[3
]}

Del Rosso, James ^{[4
]}

Draelos, Zoe D. ^{[5
]}

Eichenfield, Lawrence F. ^{[6
]}

Kircik, Leon H. ^{[7
,8
,9
,10
]}

Lebwohl, Mark G. ^{[7
]}

Gooderham, Melinda ^{[11
,12
]}

Green, Lawrence J.

Hebert, Adelaide A. ^{[14
]}

Vender, Ronald B. ^{[15
]}

Zirwas, Matthew ^{[16
,17
]}

Simpson, Eric L. ^{[13
,18
]}

Gold, Linda Stein ^{[19
]}

Seal, Melissa ^{[20
]}

Snyder, Scott ^{[20
]}

Osborne, David W. ^{[20
]}

Burnett, Patrick ^{[20
]}

Higham, Robert C. ^{[20
]}

Chu, David H. ^{[20
]}

Berk, David R. ^{[20
]}

机构：

[1] Yale Univ, Dept Dermatol, New Haven, CT USA

[2] Yale Univ, Program Translat Biomed, New Haven, CT USA

[3] Therapeut Clin Res, San Diego, CA USA

[4] JDR Dermatol Res, Las Vegas, NV USA

[5] Dermatol Consulting Serv, High Point, NC USA

[6] Univ Calif San Diego, Radys Childrens Hosp San Diego, Dept Dermatol & Pediat, San Diego, CA USA

[7] Icahn Sch Med Mt Sinai, New York, NY USA

[8] Indiana Med Ctr, Indianapolis, IN USA

[9] Phys Skin Care PLLC, Louisville, KY USA

[10] Skin Sci PLLC, Louisville, KY USA

[11] SkiN Ctr Dermatol, Prob Med Res, Peterborough, ON, Canada

[12] Queens Univ, Peterborough, ON, Canada

[13] George Washington Univ, Sch Med, Rockville, MD USA

[14] UT Hlth McGovern Med Sch, Houston, TX USA

[15] Dermatrials Res Inc, Hamilton, ON, Canada

[16] Dermatologists Cent States, Prob Med Res, Bexley, OH USA

[17] Ohio Univ, Bexley, OH USA

[18] Oregon Hlth & Sci Univ, Portland, OR USA

[19] Henry Ford Med Ctr, Detroit, MI USA

[20] Arcutis Biotherapeut Inc, Westlake Village, CA USA

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 190卷

关键词：

topical roflumilast; atopic dermatitis; psoriasis; seborrheic dermatitis; local tolerability;

D O I：

10.1093/bjd/ljad498.012

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

504

引用

页码：II9 / II10

页数：2

共 25 条

[21] Onset and Long-Term Maintenance of Optimal Itch Response in Adult Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab: Post Hoc Analysis from Two Phase 3 Trials
Staender, Sonja
Yosipovitch, Gil
Simpson, Eric L.
Kim, Brian S.
Kabashima, Kenji
Thaci, Diamant
Metz, Martin
Chen, Zhen
Hagen, Sandra
Bastian, Mike
ADVANCES IN THERAPY, 2025, : 1800 - 1810
[22] Amlitelimab (an anti-OX40 ligand antibody) vs placebo in patients with moderate-to-severe atopic dermatitis: study design of phase 3 OCEANA clinical trials COAST 1/2, SHORE, AQUA, and ESTUARY
Gold, Linda Stein
Weidinger, Stephan
Staumont-Salle, Delphine
Nakajima, Saeko
Simpson, Eric L.
Weller, Marjolein de Bruin
Davey, Sonya
Rahawi, Kassim
Bernigaud, Charlotte
BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : 59 - 60
[23] A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up) An interim 24-week analysis
Katoh, Norito
Ohya, Yukihiro
Murota, Hiroyuki
Ikeda, Masanori
Hu, Xiaofei
Ikeda, Kimitoshi
Liu, John
Sasaki, Takuya
Chu, Alvina D.
Teixeira, Henrique D.
Saeki, Hidehisa
JAAD INTERNATIONAL, 2022, 6 : 27 - 36
[24] Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study
Nakagawa, Hidemi
Nemoto, Osamu
Igarashi, Atsuyuki
Saeki, Hidehisa
Kaino, Hironobu
Nagata, Takeshi
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (04) : 823 - 831
[25] Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis
Blauvelt, Andrew
Kircik, Leon
Schlesinger, Todd
Pierce, Evangeline
Burge, Russel
Behling, Michael
Atwater, Amber Reck
Elmaraghy, Hany
Armstrong, April
JOURNAL OF DERMATOLOGICAL TREATMENT, 2025, 36 (01)

← 1 2 3 →